Cargando…
A glutamine ‘tug-of-war’: targets to manipulate glutamine metabolism for cancer immunotherapy
Within the tumour microenvironment (TME), there is a cellular ‘tug-of-war’ for glutamine, the most abundant amino acid in the body. This competition is most evident when considering the balance between a successful anti-tumour immune response and the uncontrolled growth of tumour cells that are addi...
Autores principales: | Pallett, Laura J, Dimeloe, Sarah, Sinclair, Linda V, Byrne, Adam J, Schurich, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444990/ https://www.ncbi.nlm.nih.gov/pubmed/34541580 http://dx.doi.org/10.1093/immadv/ltab010 |
Ejemplares similares
-
Peanut oral immunotherapy: current trends in clinical trials
por: Reinwald, Simone, et al.
Publicado: (2022) -
TIGIT-based immunotherapeutics in lung cancer
por: Patel, Akshay J, et al.
Publicado: (2023) -
A summary of current NKG2D-based CAR clinical trials
por: Curio, Sophie, et al.
Publicado: (2021) -
An overview of CAR T-cell clinical trial activity to 2021
por: Adami, Antonella, et al.
Publicado: (2021) -
Upcoming immunotherapeutic combinations for B-cell lymphoma
por: Greve, Patrick, et al.
Publicado: (2021)